Maetzel A - Search Results

1

Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial.

Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Maetzel A, et al. Pharmacoeconomics. 2002;20(1):61-70. doi: 10.2165/00019053-200220010-00006. Pharmacoeconomics. 2002. PMID: 11817993 Clinical Trial.

2

Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.

Osiri M, Kamolratanakul P, Maetzel A, Tugwell P. Osiri M, et al. Among authors: maetzel a. Rheumatol Int. 2007 Sep;27(11):1063-9. doi: 10.1007/s00296-007-0342-5. Epub 2007 Apr 14. Rheumatol Int. 2007. PMID: 17440729

3

The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.

Osiri M, Maetzel A, Tugwell P. Osiri M, et al. Among authors: maetzel a. J Rheumatol. 2007 Jan;34(1):57-63. Epub 2006 Dec 15. J Rheumatol. 2007. PMID: 17183621

4

Towards a reference case for use in future economic evaluations of interventions in osteoarthritis.

Drummond M, Maetzel A, Gabriel S, March L. Drummond M, et al. Among authors: maetzel a. J Rheumatol Suppl. 2003 Dec;68:26-30. J Rheumatol Suppl. 2003. PMID: 14712619 Review. No abstract available.

5

OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis.

Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V, Tugwell P; Patient Perspective Group. Gabriel S, et al. Among authors: maetzel a. J Rheumatol. 2003 Apr;30(4):886-90. J Rheumatol. 2003. PMID: 12672223 Review.

6

Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.

Benucci M, Stam WB, Gilloteau I, Sennfält K, Leclerc A, Maetzel A, Lucioni C. Benucci M, et al. Among authors: maetzel a. Clin Exp Rheumatol. 2013 Jul-Aug;31(4):575-83. Epub 2013 May 27. Clin Exp Rheumatol. 2013. PMID: 23711100 Clinical Trial.

7

Cost-effectiveness estimates reported for tumor necrosis factor blocking agents in rheumatoid arthritis refractory to methotrexate--a brief summary.

Maetzel A. Maetzel A. J Rheumatol Suppl. 2005 Jan;72:51-3. J Rheumatol Suppl. 2005. PMID: 15660469 Review.

8

Use of mainstream nonpharmacologic treatment by patients with arthritis.

Li LC, Maetzel A, Pencharz JN, Maguire L, Bombardier C; Community Hypertension and Arthritis Project (CHAP) Team. Li LC, et al. Among authors: maetzel a. Arthritis Rheum. 2004 Apr 15;51(2):203-9. doi: 10.1002/art.20244. Arthritis Rheum. 2004. PMID: 15077260

9

Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics.

Stone MA, Inman RD, Wright JG, Maetzel A. Stone MA, et al. Among authors: maetzel a. Arthritis Rheum. 2004 Jun 15;51(3):316-20. doi: 10.1002/art.20414. Arthritis Rheum. 2004. PMID: 15188313

10

Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion.

Maetzel A. Maetzel A. Can J Gastroenterol. 2003 May;17(5):335-8. doi: 10.1155/2003/942819. Can J Gastroenterol. 2003. PMID: 12772009

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results